AN ANESTHESIA DISPLAY FOR A SPACE STAnON: CLINICAL v ALIDA nON OF NEUROMUSCULAR
BLOCKADE MODELS
Rose Mills
Department of Anesthesiology
University of Utah
Salt Lake City, UT 84112
Abstract
An anesthesia drug display that shows the predicted
effects of medication may be extremely useful on a
space station and in situations where an inexperienced
person could be performing experiments on animals or
emergency treatments to fellow astronauts. Such a drug
display shows drugs given and predicts their effects on
the person or animal. In order for such a display to be
useful, the predictions must be validated to ensure
accuracy of and instill confidence in those who use the
display. This study consists of validation ofrocuronium
which is a drug used for neuromuscular blockade
(muscle relaxation). The effects of this drug have
currently been studied on 12 patients. Qualitatively, the
effects of this drug appear to be in line with the kinetic
model predictions. Data will be gathered from more
patients and will be statistically analyzed and compared
with the model predictions for validation.

Introduction
On the space station, animals may be put to sleep for
biology experiments such as dissections or small
implant surgeries. Humans may also be anesthetized in
the case of a painful accident. Astronauts come from all
disciplines and rarely, if ever, are trained in
anesthesiology. An anesthesia display such as the one
developed in our lab (Fig. 1) could be extremely useful
in such a situation. Either the drugs given can be
automatically tracked or the astronauts could enter the
information by hand, stating what drug was given at
what time. The anesthesia drug display could then
calculate in real time what the predicted effects of the
drug are on the animal or astronaut.

Figure 1. Anesthesia Drug Display Prototype. The
bottom line shows an example of the muscle
relaxants.

The drug display currently shows the administration
and effects of three different drugs: measuring
sedation, pain, and muscle relaxation. The y-axes of
the graphs show the amount of drug, and the x-axes
are time. The vertical lines show a bolus of the drug,
and then the solid line is the predicted drug effect site
concentration (from the model). The dotted lines
show what the drug levels will be in the near future,
allowing time for the anesthesiologist to better think
ahead and adjust medications if necessary. On the far
right of the display, the predicted clinical effect is
shown.
During surgery or any kind of serious treatment
anesthesia may be used for sedation (rendering the
patient unconscious and unaware of their
surroundings), analgesia (pain medication), or for
neuromuscular blockade (muscle relaxation). The
drug display shows this information in real time and
may eventually adapt to specific patients due to age,
weight, height, gender, and drug sensitivity levels.
The plot on the left shows the drug concentrations
predicted in the subject's body, while the plot on the
right shows the predicted effect of the patient to the
drug given. In the case of muscle relaxants, a
commonly used measure of effect called Train-offour (TOF) is displayed.
The purpose of relaxing a patient is to avoid
unwanted muscular responses. One example ofthis is
intubation '. As the anesthesiologist places a tube
down the patient's throat and connects it to a
ventilator, the patient may have a gag reflex. Another
possible reaction would be contractions in the
abdomen due to a surgical stimulus'. The doctor does
not want a person's (or animal's) abdomen to
contract while he has sensitive surgical instruments
(i.e. a knife) in the area. Muscle relaxants
(neuromuscular blocking agents) suppress reactions
like this to allow easier care and management by
healthcare professionals 2 •
Monitoring of neuromuscular blockade and its effects
is most often accomplished with train offour
stimulation and measurement. TOF measurement
consists of four short stimulations, which cause the
adductor pollicis (thumb and index finger) to twitch
four times 3 . As the muscle relaxant takes effect, the

patient response reduces to three twitches, then two,
one, and finally zero. At zero twitches the
neuromuscular blockade is in full effect and the patient
is very relaxed and muscles should not respond to a
given stimuli. At four twitches the TOF ratio is used.
This is a measure of the strength ofthe fourth twitch
divided by the strength of the first twitch. Using this
measure allows more fidelity in determining how close
to normal a person is with respect to neuromuscular
function. A ratio of 100 percent means that their
neuromuscular function is normal and they have four
full twitches. The lower the ratio, the more relaxed a
person is and the weaker they feel and respond to a
given stimulus.

electrode performance. As soon as the patient loses
consciousness, the electrodes are placed on the arm at
the ulnar nerve (a mini stimulator is used to ensure
that the nerve is found and the electrodes are placed
optimally). Figure 2 shows the electrode and sensor
placement. The monitor calibrates the sensor by
finding the supramaximal current with 100 Ilsec
pulses. Train-of-four measurements are taken at 20second intervals throughout the case. Before the
patient regains consciousness, the sensor and
electrodes are taken off of the patient.

The models used to predict patient reactions to the drug
can be split into two categories: pharmacokinetic and
pharmacodynamic4 • Pharmacokinetic models are those
that predict the concentration of the drug in the patient,
and the pharmacodynamic models take this drug
concentration and predict an effect on the patient at any
given concentration.
The pharmacokinetic model used in this study is the
Plaud two compartment model. The two compartments
are the bloodstream and the effect site in the body. The
model includes parameters which account for
equilibration between these compartments. The drug
display is the same implementation as Stanpump, a well
known anesthesia modeling simulation
The pharmacodynamic model used this study is still
being developed. The first step to this development is
using the Hill equation to calculate the strength of the
fIrSt twitch (from the effect site drug concentration, at
the hand)3. From this information the train of four count
and then ratio may be calculated.

Methods
To date there have been 12 subjects, out of a total of24
for the study. The patient population is a healthy set of
laparoscopic patients (most are gall bladder removals
and hernias). Data collected includes all drugs given to
the patient, as well as vital signs such as blood pressure,
heart rate, and any patient responses throughout the
surgery. The neuromuscular data consists of train-offour monitoring with the Datex-Ohmeda Electrosensor
and NMT module.
During preparation for surgery in the operating room,
the sensor is placed on the patient's thumb and index
finger and taped in place. A temperature sensor is
placed on the palm, and the arm is then wiped with an
alcohol pad to remove oil from the skin and allow better

Figure 2. Train of four stimulator and sensor.
(Image source www.datex-ohmeda.com.)

Throughout the surgery data is collected with a
laptop through Rugloop, which is a program that
collects all data from the Datex monitor.

Preliminary Results and Conclusions
The following graphs are of one patient's
neuromuscular data throughout a surgery. This
specific set of graphs is comparable to the others in
the dataset. Currently the analysis has taken into
consideration the tl ratio, TOF count, and TOF ratio.
The first important graph (Figure 3) shows the times
that the drugs were administered. In this case there
was a bolus ofrocuronium at the beginning of the
case (the spike at about 700 seconds). The spike at
the end of the case is due to administration ofa
reversal agent, neostygmine.
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Figure 3. Drug administration. The first spike is due
to the muscle relaxant, rocuronium. The second
spike is the reversal agent, neostygmine.
The tI ratio shows the strength of the first twitch to the
baseline/calibrated value. This measure shows the quick
onset of muscle relaxation effects, as soon as
rocuronium was delivered. It is clear that before
rocuroruum administration, the twitch was at or near
100% of its original value. There is a slight delay after
administration but then this twitch quickly disappears
(Figure 4). The slow return of a full strength twitch as
the effects of the drug wear off is also apparent.
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Figure 5. Effect site drug concentration calculated
with the Plaud pharmacokinetic model. Train of
four count is also shown. Note that as the drug
levels are high, the number oftwitches decrease,
and that there is a slight delay in this process.
At the beginning of the surgery, the patient had 4
twitches showing that their neuromuscular function is
normal. As predicted drug levels increase, there is a
slight delay but the twitch count decreases as the
patient's reflexes decrease. The twitch count rises as
drug concentration levels decline and the
neuromuscular function returns to normal.
At the point where there are four twitches, the train of
four ratio is used. This is a measure of the strength of
the fourth twitch divided by the strength of the fIrst
twitch. As the muscle relaxant begins to effect the
patient, this ratio decreases. The ratio increases to
100% when neuromuscular function returns to
norinal. Figure 6 shows the results of this
measurement.
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Figure 4. The tl ratio is shown above. This is the
quantitative value showing the strength of the first
twitch. Note that it declines rapidly and then
recovers more slowly.
The phannacokinetic model used to predict drug
concentrations is the Plaud model, and the drug display
has been tested against the Stanpump implementation
for accuracy. Figure 5 shows the pharmacokinetics
predicted throughout the case. These drug concentration
levels are what is shown on the drug display.
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Figure 6. TOF ratio. Zeros are when the TOF
count was less than four. Note that this ratio drops
off sharply and rises back up slowly.

There is a slight delay after rocuronium administration,
but the ratio does decline rapidly as the muscles
become relaxed. The ratio slowly increases toward
normal function until the reversal agent is given. This
information is consistent with the characteristics of
rocuronium I. Once this occurs the slope sharply
increases as neuromuscular function quickly returns to
normal. In this case the data ends at 60% recovery due
to shutting off the equipment. (This maximizes patient
comfort as they wake up from the anesthesia).
A qualitative look at these results are promising for
drug model validation. Some work will be done to look
at the pharmacodynamic model of predicted TOF count
vs. actual TOF count. Statistical methods of analyzing
the data are being explored and will be performed soon.

Future Work
Once the drug models are validated, the display will be
tested in the operating room to show that this is an
extremely valuable tool. Models may also be adapted
according to patient parameters such as height, weight,
and age. This will make the display patient specific and
therefore more accurate and useful.
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